OTC · Biotechnology

Defence Therapeutics Inc. (DTCFF) Stock

$0.29 +9.96% OTC: DTCFF Healthcare

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases.

Valuation

MetricValue
Price$0.29
Market Cap$22.25M
P/E Ratio-3.58
P/B Ratio4.36
P/S Ratio0.00
EPS (TTM)$-0.05
52-Week High$0.78
52-Week Low$0.25
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE400.00%
ROA-67.17%
ROCE-53.54%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.29
Current Ratio3.37

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-3.0M$-7.0M$-6.0M$-13.0M$-3.0M
Net Profit$-3.0M$-7.0M$-7.0M$-13.0M$-4.0M
EPS$-0.11$-0.20$-0.17$-0.30$-0.05
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$6.0M$1.0M$4.0M$0$2.0M
Total Liabilities$0$1.0M$2.0M$4.0M$3.0M
Cash$5.0M$1.0M$3.0M$0$1.0M
Borrowings$0$0$2.0M$2.0M$2.0M

Latest News

Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform TMX Newsfile · Jul 8, 2026 Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions TMX Newsfile · Jun 17, 2026 Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors TMX Newsfile · Jun 3, 2026 Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors TMX Newsfile · Jun 1, 2026 Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian TMX Newsfile · May 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-6.0M$-8.0M$-4.0M$-3.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$3.0M$0$-1.0M$0$0
Net Cash Flow$4.0M$-5.0M$2.0M$-3.0M$1.0M
Free Cash Flow$-2.0M$-6.0M$-8.0M$-4.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.09
EV / EBITDA-4.82
FCF Yield-12.29%
Quick Ratio3.37
Interest Coverage-20.51
Return 1Y-47.64%
Return 3Y-88.19%
Return 5Y—

Ownership

Insiders Held12.82%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BBIXFBonus Biogroup Ltd. $0.10 +0.00% -25.29 $110.95M 0.00%
CLYYFCelyad Oncology S.A. $0.20 +0.00% 14.03 $8.95M 0.00%
CYYNFCynata Therapeutics Limited $0.00 — -0.33 $973817 0.00%
FNCHFinch Therapeutics Group, Inc. $9.60 -3.71% -1.11 $15.42M 0.00%
MBXBFMicrobix Biosystems Inc. $0.22 +0.00% -7.44 $30.25M 0.00%

About Defence Therapeutics Inc.

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein-based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Montreal, Canada.

Defence Therapeutics Inc. is headquartered in CA.

Defence Therapeutics Inc. (DTCFF) stock trades at $0.29 with a market capitalization of $22.25M. The stock is valued at a price-to-earnings (P/E) ratio of -3.58, price-to-book of 4.36, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.25 and $0.78, and currently trades 62.8% below its 52-week high.

On profitability, Defence Therapeutics Inc. generates a return on equity (ROE) of 400.00% — well above the market average, a sign of a high-quality business, return on capital employed of -53.54%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.defencetherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides